SAMSUNG EPIS HOLDINGS Co., Ltd.
Financials
Valuation Metrics
SAMSUNG EPIS HOLDINGS Co., Ltd.'s Market Cap is ₩9.2T. Ranked #75 of 2,419 in KR market (top 3%), #71 of 781 on KOSPI (top 9%), #4 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 9.16T KRW | KR#75/2,419 Sec#4/231 |
| Revenue | 251.69B KRW | KR#914/2,419 Sec#49/231 |
| Net Income | 85.31B KRW | KR#278/2,419 Sec#16/231 |
| Total Assets | 7.72T KRW | KR#139/2,419 Sec#3/231 |
| Net Assets | 5.91T KRW | KR#89/2,419 Sec#3/231 |
| Value | ||
| P/E | 107.33x | KR#1,486/2,419 Sec#99/231 |
| P/B | 1.55x | KR#1,761/2,419 Sec#122/231 |
| P/S | 36.38x | KR#2,361/2,419 Sec#193/231 |
| FCF Yield | -1.20% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | 1.44% | KR#1,454/2,419 Sec#99/231 |
| ROA | 1.11% | KR#1,387/2,419 Sec#100/231 |
| Op. Margin | -25.29% | KR#2,153/2,419 Sec#151/231 |
| Financial Health | ||
| Debt Ratio | 30.64% | KR#604/2,419 Sec#70/231 |
| Total Debt | 377.00B KRW | KR#356/2,419 Sec#15/231 |
| FCF | -110.08B KRW | KR#2,139/2,419 Sec#211/231 |
| Cash | 131.30B KRW | KR#384/2,419 Sec#17/231 |
| Current Ratio | 1.36x | KR#1,313/2,419 Sec#138/231 |
| Performance | ||
| 1M Return | 2.22% | KR#874/2,419 Sec#75/231 |
| From 52W High | -52.39% | KR#1,587/2,419 Sec#130/231 |
| 1Y MDD | -55.85% | KR#1,258/2,419 Sec#104/231 |
| Trading | ||
| Volume | 22,830 shares | KR#1,556/2,419 Sec#153/231 |
| Trading Value | 8.50B KRW | KR#288/2,419 Sec#26/231 |
| Foreign Own. | 5.56% | KR#783/2,419 Sec#73/231 |
| Per Share | ||
| EPS | 3,429 KRW | KR#305/2,419 Sec#20/231 |
| BPS | 237,341 KRW | KR#58/2,419 Sec#1/231 |
Company Info
Samsung Episholdings is a bio investment holding company established in 2025, spun off from Samsung Biologics, and is engaged in biotechnology platform development. The company plans to intensively foster new businesses by leveraging its experience in growing its subsidiary, Samsung Bioepis, into a global top 5 biosimilar development company within 10 years through an R&D-focused biotech strategy. Samsung Bioepis has successfully developed and launched 11 biosimilar products, the most worldwide, demonstrating successful biosimilar development and commercialization. The company is headquartered in Yeonsu-gu, Incheon.